ZENO - Zenosense, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.41
-0.02 (-4.09%)
At close: 3:14PM EDT
Stock chart is not supported by your current browser
Previous Close0.43
Open0.42
Bid0.00 x 0
Ask0.00 x 0
Day's Range0.41 - 0.43
52 Week Range0.15 - 0.89
Volume39,628
Avg. Volume255,732
Market Cap11.083M
Beta7.34
PE Ratio (TTM)N/A
EPS (TTM)-0.02
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Zacks Small Cap Research6 days ago

    Zenosense’s MIDS Cardiac Could Revolutionize Cardiac Troponin Testing

    OTC:ZENO Zenosense, Inc. (OTC:ZENO) is a healthcare technology company located in Valencia, Spain.  The company’s main focus is a novel hand-held point-of-care (POC) cardiac diagnostic device called MIDS ...

  • GlobeNewswire12 days ago

    Zenosense Trading on the OTCQB Venture Market

    Zenosense, Inc. (OTCQB: ZENO, "Zenosense", the "Company"), a healthcare technology company focused on the development and commercialization of the MIDS Cardiac™ hand-held device for the early detection of heart attack at the Point of Care, is pleased to announce that the Company is now trading on the OTC Markets Group OTCQB “Venture Market”. The OTCQB is recognized as an Established Public Market by the U.S. Securities and Exchange Commission and is a leading market for entrepreneurial and development stage U.S. and international companies.

  • Newsfile24 days ago

    NetworkNewsAudio Announces Audio Press Release (APR) on Zenosense Demonstrating Impressive Results with MIDS Cardiac

    New York, New York--(Newsfile Corp. - June 28, 2018) - NetworkNewsAudio announces the Audio Press Release (APR) titled "Diagnostics Play Critical Role in Medical Sector," featuring Zenosense (OTC Pink: ZENO). To hear the NetworkNewsAudio version, visit http://nnw.fm/kqyU7To read the original editorial, visit http://nnw.fm/8ZAlrDeveloped by the Company's MIDS Medical Limited joint venture (MML) based at the prestigious Sci-Tech Daresbury campus in the United Kingdom, MIDS Cardiac is a handheld POC technology for the detection of ...

  • GlobeNewswire25 days ago

    NetworkNewsWire Announces Publication on Innovative Advancements in Med Tech Diagnostics

    NEW YORK, June 27, 2018 (GLOBE NEWSWIRE) -- via NetworkWire – NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring Zenosense (ZENO), a client of NNW and healthcare technology developer focused on transformational, disruptive medical diagnostic projects. The introduction of accurate handheld devices such as MIDS Cardiac is an important step for the POC market. Many of the most effective detection systems are too large and unwieldy to be used at the POC.

  • GlobeNewswirelast month

    Zenosense, Inc.: Breakthrough Quantitative MIDS Testing Results

    Zenosense, Inc. (OTC PINK: ZENO) ("Zenosense", the "Company"), a healthcare technology company focused on the development and commercialization of the MIDS Cardiac™ hand-held technology for the early detection of heart attack at the Point of Care, is pleased to announce that its MIDS Medical Ltd. joint venture ("MML") has successfully completed a second testing round of its revised detection system. In 2017 the first next generation troponin assay for the early diagnosis of heart attack was approved for use in the U.S. by the FDA.

  • GlobeNewswire2 months ago

    Zenosense, Inc.: MIDS Shareholder Update 

    Zenosense, Inc. (OTC PINK: ZENO) ("Zenosense", the "Company"), a healthcare technology company primarily focused on the development and commercialization of MIDS Cardiac™, a Point of Care handheld device for the early detection of certain cardiac event biomarkers.  We believe that MIDS Cardiac will significantly accelerate the triage, diagnosis, treatment and disposition of patients reporting chest pain symptomatic of acute myocardial infarction (heart attack). The MIDS Cardiac development is being carried out by our MIDS Medical Limited joint venture ("MML") based at Sci-Tech, Daresbury (UK). The Company notes the recent decline in its share price and knows of no operational reason for this. The development by MML of the MIDS technology platform is progressing as planned.

  • Marketwired8 months ago

    Zenosense, Inc.: MIDS Hybrid Strip - Successful Initial Test Results

    Zenosense, Inc. , a healthcare technology company primarily focused on the development and commercialization of MIDS Cardiac™, a Point of Care handheld device for the early detection of certain cardiac ...